Research
Hormonal
Unimolecular GLP-1/GCG dual agonist and GLP-1/GIP/GCG triple agonist may offer superior weight loss efficacy over GLP-1 agonist.
Practitioners should consider these new agonists for potentially better weight loss outcomes.
StrongSupportsmedium confidence
Emerging data suggests that unimolecular GLP-1/glucagon (GCG) dual agonist, as well as GLP-1/GIP/GCG triple agonist, may offer superior weight loss efficacy over GLP-1 agonist.
Why this rating
Based on the review of pharmacotherapy strategies.
Source
Why does <scp>GLP</scp> ‐1 agonist combined with <scp>GIP</scp> and/or <scp>GCG</scp> agonist have greater weight loss effect than <scp>GLP</scp> ‐1 agonist alone in obese adults without type 2 diabetes?
Yuchen Jiang et al. · Diabetes Obesity and Metabolism · 2024
reviewCited 18×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →